Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease despite the May 7 target date for a decision, the company confirmed to Endpoints ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...

Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...

Gilead is the latest drugmaker to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in ...

FDA advisors to meet May 22 on Covid vaccine strain selection amid scrutiny from Kennedy's HHS, as Novavax awaits approval ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.